Alivus Life Sciences Ltd Q1 FY27 Results Analysis: EBITDA Margin Expands 650 bps, PAT Jumps 31.7%

Alivus Life Sciences Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 640.41 Cr (+6.40% YoY) and PAT growth of +31.70% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quarter Snapshot

Alivus delivered a strong margin beat with EBITDA margin expanding 650 bps YoY to 36.6%, well above the 30-32% guidance band, driven by a 520 bps improvement in material costs. PAT grew 31.7% YoY, though revenue growth of 6.4% was at the lower end of the high single-digit guidance, and QoQ revenue declined 7.1% due to GPL volatility. The debt-free balance sheet and structural margin improvement provide a solid foundation, but revenue acceleration in H2 is needed to meet full-year guidance.

Key Investment Insights

Key Positives

• EBITDA margin expanded 650 bps YoY to 36.6%, the highest in five quarters
• Operating EBITDA margin (ex-other income) expanded 450 bps YoY to 33.1%, confirming structural improvement
• PAT grew 31.7% YoY to Rs.160.08 Cr, with EPS rising 31.6% to Rs.13.04
• Material cost ratio improved 520 bps YoY to 39.5% of revenue, driving margin expansion
• Debt-free balance sheet with Rs.782.40 Cr cash as of March 31, 2026

Risk Factors

• Revenue declined 7.1% QoQ from Q4FY26 peak, consistent with GPL business volatility
• Revenue growth of 6.4% is at the lower end of the high single-digit guidance range, requiring acceleration in H2 to meet full-year guidance